Ling Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ling Xu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Junping Zhang
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine, Tianjin, China
1 shared publication - Meifang Wu
The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
1 shared publication - Meng Li
School of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, China
1 shared publication - Qiang Wang
The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
1 shared publication - Shichao Lv
Department of Geriatrics, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine, No 88 Changling Road, Tianjin, 300381, China, 86 13920127740
1 shared publication - Xiao-Jing Wang
Institute of Materia Medica, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan 250000, China
1 shared publication
Latest Publications
- Open Access
- 16 June 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-10
QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats
Pressure-overloaded myocardial hypertrophy is an independent risk factor for various cardiovascular diseases (CVDs), such as heart failure (HF), arrhythmia, and even sudden death. It is reported that QiShenYiQi pill (QSYQ) is widely used in the treatment of CVDs and can prevent pathological hypertrophy of myocardium, but its specific mechanism is still unclear. In this study, a rat model of myocardial hypertrophy was established through the pressure overload caused by abdominal aortic constriction in Wistar rats. The rats were randomly divided into model group, valsartan group, and QSYQ group, and sham-operated animals served as the control group. At the 4 and 8 weeks of intervention, the general morphology of the heart, myocardial collagen content, collagen volume factor (CVF), collagen type I, collagen type III, myocardial pathological changes, and the expression of ANP, β-MHC, TGF-β1, and CTGF were analyzed, respectively, in order to explore the possible effect of QSYQ on the mechanism of myocardial hypertrophy. We observed that QSYQ could effectively improve myocardial hypertrophy in pressure-overloaded rats, which was related to the regulatory mechanism of TGF-β1 and CTGF.
- 16 June 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-10
Open AccessQiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats
Pressure-overloaded myocardial hypertrophy is an independent risk factor for various cardiovascular diseases (CVDs), such as heart failure (HF), arrhythmia, and even sudden death. It is reported that QiShenYiQi pill (QSYQ) is widely used in the treatment of CVDs and can prevent pathological hypertrophy of myocardium, but its specific mechanism is still unclear. In this study, a rat model of myocardial hypertrophy was established through the pressure overload caused by abdominal aortic constriction in Wistar rats. The rats were randomly divided into model group, valsartan group, and QSYQ group, and sham-operated animals served as the control group. At the 4 and 8 weeks of intervention, the general morphology of the heart, myocardial collagen content, collagen volume factor (CVF), collagen type I, collagen type III, myocardial pathological changes, and the expression of ANP, β-MHC, TGF-β1, and CTGF were analyzed, respectively, in order to explore the possible effect of QSYQ on the mechanism of myocardial hypertrophy. We observed that QSYQ could effectively improve myocardial hypertrophy in pressure-overloaded rats, which was related to the regulatory mechanism of TGF-β1 and CTGF.